Philip James Wealth Mangement LLC Buys New Shares in Pfizer Inc. (NYSE:PFE)

Philip James Wealth Mangement LLC bought a new position in shares of Pfizer Inc. (NYSE:PFE - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 349,297 shares of the biopharmaceutical company's stock, valued at approximately $10,109,000. Pfizer makes up 1.2% of Philip James Wealth Mangement LLC's holdings, making the stock its 17th biggest position.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. LGT Group Foundation grew its position in Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company's stock worth $20,786,000 after buying an additional 18,274 shares in the last quarter. Radnor Capital Management LLC purchased a new position in shares of Pfizer in the 3rd quarter worth about $2,972,000. Kornitzer Capital Management Inc. KS boosted its holdings in shares of Pfizer by 2.4% in the 3rd quarter. Kornitzer Capital Management Inc. KS now owns 1,168,315 shares of the biopharmaceutical company's stock worth $33,811,000 after purchasing an additional 27,562 shares in the last quarter. Capital Advisors Inc. OK boosted its holdings in shares of Pfizer by 3.5% in the 3rd quarter. Capital Advisors Inc. OK now owns 1,439,745 shares of the biopharmaceutical company's stock worth $41,666,000 after purchasing an additional 48,314 shares in the last quarter. Finally, Creative Planning boosted its holdings in shares of Pfizer by 17.1% in the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company's stock worth $52,692,000 after purchasing an additional 266,167 shares in the last quarter. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the company. Daiwa America upgraded Pfizer from a "moderate buy" rating to a "strong-buy" rating in a report on Wednesday, August 7th. Cantor Fitzgerald restated an "overweight" rating and set a $45.00 target price on shares of Pfizer in a report on Wednesday, October 23rd. Evercore ISI upgraded Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Wells Fargo & Company increased their target price on Pfizer from $28.00 to $30.00 and gave the company an "equal weight" rating in a report on Wednesday, July 31st. Finally, StockNews.com upgraded Pfizer from a "hold" rating to a "buy" rating in a report on Wednesday, October 9th. Eight research analysts have rated the stock with a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $33.58.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, with a total value of $28,240.00. Following the acquisition, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 0.00 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company's stock.

Pfizer Stock Down 2.7 %

Shares of PFE traded down $0.73 on Friday, reaching $26.73. The stock had a trading volume of 55,867,826 shares, compared to its average volume of 37,583,031. The firm has a market capitalization of $151.48 billion, a price-to-earnings ratio of 36.11, a price-to-earnings-growth ratio of 0.87 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.60 and a current ratio of 1.00. The company has a 50-day simple moving average of $28.96 and a 200-day simple moving average of $28.64. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating analysts' consensus estimates of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analysts' expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm's revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter last year, the business posted ($0.17) EPS. Sell-side analysts predict that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 dividend on an annualized basis and a yield of 6.29%. The ex-dividend date is Friday, November 8th. Pfizer's dividend payout ratio (DPR) is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.